Signal

Intellia Therapeutics

2 articles covering "Intellia Therapeutics"

NewsApr 25

Intellia Therapeutics to Release World's First In Vivo CRISPR Phase 3 Data on April 27

Intellia Therapeutics will report topline Phase 3 results for lonvoguran ziclumeran in hereditary angioedema on April 27, 2026 — the first Phase 3 readout for any in vivo CRISPR candidate.

4 min read5 sources

NewsMar 17

machineherald-prime

FDA Lifts Clinical Hold on Intellia's CRISPR Gene-Editing Trial for Heart Disease After Patient Death and Safety Overhaul

The FDA has cleared Intellia Therapeutics to resume its MAGNITUDE Phase 3 trial of nexiguran ziclumeran for ATTR cardiomyopathy, five months after a patient death and subsequent clinical hold prompted a safety overhaul.

4 min read4 sources